Sharenet Sites 
Sharenet Sites
Production of the First Cryo-Vacc™ Commence for DPD Laser
RENERGEN LIMITED
Incorporated in the Republic of South Africa
(Registration number: 2014/195093/06)
JSE Share Code: REN
A2X Share Code: REN
ISIN: ZAE000202610
LEI: 378900B1512179F35A69
Australian Business Number (ABN): 93 998 352 675
ASX Share code: RLT
("Renergen" or "the Company")
PRODUCTION OF THE FIRST CRYO-VACC™ COMMENCE FOR DPD LASER
Domestic natural gas and helium producer Renergen Limited ("Renergen” or the "Company")
and DPD Laser (Limited) ("DPD Laser") have entered into an agreement for the manufacture
and purchase of the first 110 Cryo-Vacc™ cases, following the launch of Renergen's Cryo-
Vacc™ storage solution (see ASX announcement dated 15 February 2021).
DPD Laser is one of South Africa's leading express courier companies that has been proudly
serving South Africa for over 30 years.
The key terms of the agreement with DPD Laser are:
• The agreement relates to a fixed purchase of 110 Cryo-Vacc™ cases in a combination
of all three sizes; and
• The Cryo-Vacc™ cases will be delivered in May.
There are no other material conditions to the agreement.
Whilst the agreement with DPD Laser is not considered material to the Company from a
revenue perspective, it represents a significant milestone for the Company regarding the
commencement of manufacturing of the Cryo-Vacc™ to its customers.
The agreement has been completed ahead of the launch of Phase 2 vaccination program for
SA. Renergen has commenced construction of the 110 Cryo-Vacc™ cases for delivery to DPD
Laser, which is expected to be completed by the end of May 2021.
DPD Laser will offer the Cryo-Vacc™ cases to the market on a monthly rental arrangement,
including the maintenance, delivery, and collection of the Cryo-Vacc™ cases from respective
maintenance points.
The three sizes offered currently include a large case (up to 2,400 vials), a medium case (up to
1,200 vials and a smaller case (up to 240 vials) which is ideal for smaller vaccination points
such as pharmacies and medical practices.
"This is an exciting time and another milestone for Renergen, and we look forward to working
with DDP Laser in rolling out the Cryo-Vacc™.
"The prototype was put through its paces in a first validation phase and was purely focused on
temperature distribution and stability. Notably, the Cryo-Vacc™ passed successfully. We saw
areas where we could improve the design during this process and resubmitted it for another
round of validation yesterday. Many of the original components were replaced or improved
upon. We do not anticipate updating the market with this validation, as it is merely a repeat of
the previous validation using different components.
"We believe the technology works, and as time progresses, we will continue to enhance and
improve the Cryo-Vacc™ as we gain valuable data from people in the field using the product.
The analogy we see here is that version 12 of a smartphone was not the first version released;
they got there over time. Cryo-Vacc™ will continue to evolve, and this is the exciting part as it
becomes more flexible and useful in the field, which is the goal," said Renergen CEO Stefano
Marani.
DPD Laser CEO Anton Visagie said, "We have the ideal solution, storage and distribution,
given the current uncertainty on which vaccines will be used at various vaccination points
across South Africa. Our technology can handle all three required temperatures of 2-8 degrees,
-20 degrees and -70 degrees Celsius without being dependent on an external power supply for
periods between 7 and 35 days."
Johannesburg
21 April 2021
Authorised by: Stefano Marani
Chief Executive Officer
Designated Advisor
PSG Capital
For Australian Investors & Media, contact Citadel-MAGNUS
Cameron Gilenko, 0466 984 953
For South African Investors & Media, contact us on
info@renergen.co.za
+2710 045 6007
www.renergen.co.za
Date: 21-04-2021 08:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
